Statistics

Total Visits

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.54

Select a period of time:

Number of views in the range

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.5

Views

Views
September 20250
October 20252
November 20251
December 20250
January 20261
February 20260
March 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States2
Brazil2
Venezuela1
 

Top cities views

Views
Hollywood1
San Jose1
São Vicente do Sul1
Vitória1